Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chee Khoon Lee

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
JAMA Network Open|September 8, 2020
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysisPeey-Sei Kok, Doah Cho, Won-Hee Yoon, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancerPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
JCO Clinical Cancer Informatics|July 10, 2026
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping ReviewRachel Woodford, Sally Lord, Frank Lin, et al.
Breast Cancer Research and Treatment|November 23, 2018
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysisKirsty Wai Chung Lee, Sally Lord, Richard S Finn, et al.
Journal of Geriatric Oncology|May 27, 2019
Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysisLawrence Kasherman, Derrick Ho Wai Siu, Kirsty Wai Chung Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung CancerPei Ni Ding, Sarah J Lord, Val Gebski, et al.
JCO Precision Oncology|January 8, 2024
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology TrialsDerrick H W Siu, Frank P Y Lin, Doah Cho, et al.
Acta Oncologica (Stockholm, Sweden)|August 30, 2019
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapyAngelina Tjokrowidjaja, David Goldstein, H Malcolm Hudson, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
JCO Precision Oncology|July 6, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized StudiesJanene Dalrymple, Rebecca Symons, Katrin M Sjoquist, et al.
JCO Precision Oncology|January 11, 2024
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized TrialsRachel Woodford, Deborah Zhou, Peey-Sei Kok, et al.
JAMA Network Open|September 8, 2020
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysisPeey-Sei Kok, Doah Cho, Won-Hee Yoon, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancerPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
JCO Clinical Cancer Informatics|July 10, 2026
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping ReviewRachel Woodford, Sally Lord, Frank Lin, et al.
Breast Cancer Research and Treatment|November 23, 2018
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysisKirsty Wai Chung Lee, Sally Lord, Richard S Finn, et al.
Journal of Geriatric Oncology|May 27, 2019
Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysisLawrence Kasherman, Derrick Ho Wai Siu, Kirsty Wai Chung Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung CancerPei Ni Ding, Sarah J Lord, Val Gebski, et al.
JCO Precision Oncology|January 8, 2024
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology TrialsDerrick H W Siu, Frank P Y Lin, Doah Cho, et al.
Acta Oncologica (Stockholm, Sweden)|August 30, 2019
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapyAngelina Tjokrowidjaja, David Goldstein, H Malcolm Hudson, et al.
Pageof 9